Lung Cancer Resistance: Scientists Unlock Mystery of EGFR Mutations

Scientists at the A*STAR Institute of Molecular adn Cell Biology (A*STAR IMCB) in singapore have made a significant breakthrough in understanding why certain lung cancer cells develop resistance to treatment after acquiring mutations in the epidermal growth factor receptor (EGFR) gene. This finding could pave the way for more effective therapies to combat this common and often deadly form of cancer.

Understanding EGFR and Lung Cancer

Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. EGFR is a protein involved in cell growth and division. Mutations in the EGFR gene are common in NSCLC, especially in adenocarcinoma, a subtype of lung cancer. These mutations often make the cancer cells more sensitive to EGFR tyrosine kinase inhibitors (TKIs) – drugs specifically designed to block the activity of the mutated EGFR protein.

However, the initial success of EGFR TKIs is often short-lived. Most patients eventually develop resistance to these drugs, leading to cancer progression. Identifying the mechanisms behind this resistance is crucial for developing strategies to overcome it.

The Role of the Protein ‘MYC’

The A*STAR IMCB team’s research, published in Nature, reveals that the protein MYC plays a central role in driving resistance to EGFR TKIs. MYC is a well-known oncogene – a gene that can cause cancer when mutated or overexpressed.

The researchers found that EGFR mutations trigger an increase in MYC levels within the cancer cells. This elevated MYC then bypasses the need for EGFR signaling, allowing the cancer cells to continue growing and dividing even when EGFR is blocked by TKI drugs. Essentially, the cancer cells find an alternative pathway to fuel their growth.

“We discovered that EGFR-mutant lung cancer cells upregulate MYC, which then rewires cellular metabolism and promotes drug resistance,” explains Dr. Lee Kong Hian, a senior author of the study. “This finding provides a new therapeutic target for overcoming TKI resistance.”

How the Research Was Conducted

The research involved a combination of laboratory experiments using lung cancer cell lines and patient-derived tumor samples. The team employed techniques such as gene editing (CRISPR) to manipulate MYC levels and assess the impact on TKI sensitivity. They also analyzed the metabolic changes occurring in the cancer cells when MYC was upregulated.

Further examination revealed that MYC increases the uptake of glutamine, an amino acid, and enhances mitochondrial metabolism, providing the cancer cells wiht the energy they need to survive despite TKI treatment.

Implications for Future Treatments

This discovery opens up new avenues for developing more effective lung cancer treatments. Strategies to target MYC directly, or to disrupt the metabolic pathways it activates, could potentially restore sensitivity to EGFR TKIs and improve patient outcomes.

Researchers are now exploring several approaches, including:

• MYC inhibitors: Drugs that specifically block the activity of the MYC protein are under advancement, but have proven challenging to create due to MYC’s complex structure.
• Metabolic inhibitors: Targeting the metabolic pathways upregulated by MYC, such as glutamine metabolism, could starve the cancer cells and make them more vulnerable to TKIs.
• Combination therapies: Combining EGFR TKIs with drugs that target MYC or its downstream effects may be a more effective approach than using TKIs alone.

Key Takeaways

• EGFR mutations are common in lung cancer and initially make the cancer sensitive to EGFR TKIs.
• Lung cancer cells frequently develop resistance to EGFR TKIs.
• The protein MYC is a key driver of this resistance, bypassing the need for EGFR signaling.
• MYC increases glutamine uptake and enhances mitochondrial metabolism, fueling cancer cell growth.
• Targeting MYC or its metabolic effects could restore sensitivity to EGFR tkis and improve treatment outcomes.

This research represents a significant step forward in our understanding of lung cancer resistance and offers hope for the development of more effective therapies for this devastating disease.